These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2199424)

  • 41. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group.
    J Am Coll Cardiol; 1984 Dec; 4(6):1148-63. PubMed ID: 6209318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral chemotherapy in tinnitus.
    Kay NJ
    Br J Audiol; 1981 May; 15(2):123-4. PubMed ID: 7225648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Signal-averaged ECG in prediction of the short-term suppression of ventricular premature beats by Mexiletine.
    Zaliunas R; Zabiela P; Slapikas R; Vainoras A; Pentiokiniene D; Levisauskiene R; Bechtold H; Meyer U
    Int J Cardiol; 1994 Oct; 46(3):243-54. PubMed ID: 7529214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Long-term mexiletine treatment of ventricular arrhythmia in patients after myocardial infarction].
    Drazkiewicz U; Petelenz T; Axenti I; Olszowy Z
    Pol Arch Med Wewn; 1992 Mar; 87(3):157-67. PubMed ID: 1381822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A schedule for combined intravenous and oral dosing with mexiletine.
    Holt DW; Hampel G; Volans GN
    J Int Med Res; 1979; 7(2):162-4. PubMed ID: 478163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral mexiletine in high-risk patients after myocardial infarction.
    Oliver MF
    Lancet; 1981 Apr; 1(8223):787. PubMed ID: 6110993
    [No Abstract]   [Full Text] [Related]  

  • 47. Oral mexiletine in high-risk patients after myocardial infarction.
    Chamberlain DA; Jewitt DE; Julian DG; Campbell RW; Boyle DM; Shanks RG
    Lancet; 1980 Dec 20-27; 2(8208-8209):1324-7. PubMed ID: 6109149
    [No Abstract]   [Full Text] [Related]  

  • 48. [Mexiletine, an anti-arrhythmia agent for acute stage of myocardial infarction].
    Hayakawa H; Ino T
    Nihon Rinsho; 1983 Dec; 41(12):2748-55. PubMed ID: 6674559
    [No Abstract]   [Full Text] [Related]  

  • 49. Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity.
    Nora MO; Chandrasekaran K; Hammill SC; Reeder GS
    Chest; 1989 Apr; 95(4):925-8. PubMed ID: 2924630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mexiletine for treatment of chronic painful diabetic neuropathy.
    Dejgard A; Petersen P; Kastrup J
    Lancet; 1988 Jan 2-9; 1(8575-6):9-11. PubMed ID: 2891940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of oral mexiletine therapy at a 12-h dosage interval.
    Steen SN; Hughes EM; Sharon G; MacGregor TR
    Chest; 1990 Feb; 97(2):358-63. PubMed ID: 1688758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    Eur J Clin Pharmacol; 1983; 25(6):773-7. PubMed ID: 6662176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the plasma concentrations and efficacy of mexiletine and of a slow-release preparation of mexiletine in patients admitted to a coronary care unit.
    Boyle DM; Barber JM; Chapman C; Khalid I; Kinney CD; McIlmoyle EL; Salathia K; Shanks RG
    J Cardiovasc Pharmacol; 1982; 4(2):174-9. PubMed ID: 6175798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy.
    Wright JM; Oki JC; Graves L
    Ann Pharmacother; 1997 Jan; 31(1):29-34. PubMed ID: 8997461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study.
    Wallace MS; Magnuson S; Ridgeway B
    Reg Anesth Pain Med; 2000; 25(5):459-67. PubMed ID: 11009230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of intravenous mexiletine on spectra of the signal-averaged ECG.
    Zaliunas R; Zabiela P; Slapikas R; Vainoras A; Pentiokiniene D; Levisauskiene R; Bechtold H; Meyer U
    Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 2):2187-93. PubMed ID: 7845841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mexiletine.
    Campbell RW
    N Engl J Med; 1987 Jan; 316(1):29-34. PubMed ID: 3537793
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group.
    Oskarsson P; Ljunggren JG; Lins PE
    Diabetes Care; 1997 Oct; 20(10):1594-7. PubMed ID: 9314641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of a highly purified hyaluronidase preparation (GL enzyme) on electrocardiographic changes in acute myocardial infarction.
    Henderson A; Campbell RW; Julian DG
    Lancet; 1982 Apr; 1(8277):874-6. PubMed ID: 6122100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine.
    Paalman AC; Siebelink J; Roos JC; Dunning AJ
    Postgrad Med J; 1977; 53 Suppl 1():128-33. PubMed ID: 876945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.